Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance

被引：0
|
作者：
Lucien Torlot
Anna Jarzab
Johanna Albert
Ágnes Pók-Udvari
Arndt Stahler
Julian Walter Holch
Marco Gerlinger
Volker Heinemann
Frederick Klauschen
Thomas Kirchner
Jörg Kumbrink
Bernhard Küster
Andreas Jung
机构：
[1] Ludwig-Maximilians-University (LMU),Institute of Pathology
[2] German Cancer Consortium (DKTK),Chair or Proteomics and Bioanalytics
[3] Technical University of Munich,Department of Hematology, Oncology, and Cancer Immunology
[4] Charité - Universitätsmedizin Berlin,Department of Medicine III
[5] Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,Comprehensive Cancer Center Munich (CCCM)
[6] German Cancer Consortium (DKTK),Translational Oncogenomics Lab
[7] LMU Hospital,Barts Cancer Institute
[8] LMU Hospital,Gastrointestinal Cancer Unit
[9] The Institute of Cancer Research,undefined
[10] Queen Mary University of London,undefined
[11] St Bartholomew’s Hospital,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Colorectal cancer; EPHA2; Cetuximab resistance; Molecular oncology; Proteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 682
页数：13
相关论文
共 50 条
  • [41] c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
    Shah, Yatrik M.
    Van den Brink, Gijs R.
    GASTROENTEROLOGY, 2015, 149 (03) : 534 - 537
  • [42] EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice
    Chen, Zuhua
    Liu, Zhentao
    Zhang, Mengqi
    Huang, Wenwen
    Li, Zhongwu
    Wang, Shubin
    Zhang, Cheng
    Dong, Bin
    Gao, Jing
    Shen, Lin
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2440 - 2449
  • [43] LAMC2 acts as a novel therapeutic target of cetuximab in laryngeal cancer
    Wang, Qin-Ying
    Liu, Yong-Cai
    Zhou, Shui-Hong
    Chen, Hai-Hong
    NEOPLASMA, 2021, 68 (06) : 1257 - 1264
  • [44] Fibroblast growth factor receptor 2 as a novel therapeutic target for colorectal cancer cell growth
    Zenya, Naito
    Matsuda, Yoko
    Peng, Wei-Xia
    Yamahatsu, Kazuya
    Ueda, Junji
    Kawamoto, Yoko
    Teduka, Kiyoshi
    Seya, Tomoko
    Ohaki, Yoshiharu
    Ishiwata, Toshiyuki
    CANCER RESEARCH, 2011, 71
  • [45] Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer (CRC) in a novel mouse avatar model
    Vangala, Deepak B.
    Liffers, Sven T.
    Pohl, Michael
    Teschendorf, Christian
    Tannapfel, Andrea
    Schmiegel, Wolff H.
    Hahn, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
    Vitiello, P. P.
    Mele, L.
    Prisco, C.
    Cardone, C.
    Ciardiello, D.
    Poliero, L.
    Borrelli, C.
    Zanaletti, N.
    Vitale, P.
    Tirino, V.
    Papaccio, G.
    Troiani, T.
    Ciardiello, F.
    Marampon, F.
    Desiderio, V.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab
    De Falco, V.
    Giunta, E. F.
    Belli, V.
    Matrone, N.
    Napolitano, S.
    Martinelli, E.
    Vitale, P.
    Zanaletti, N.
    Terminiello, M.
    Vitiello, P. P.
    Ciardiello, F.
    Troiani, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 9 - 9
  • [48] LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer
    Doxtater, Kyle D.
    Tripathi, Manish K.
    CANCER RESEARCH, 2023, 83 (07)
  • [49] Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
    Cruz-Duarte, Raquel
    de Almeida, Catia Rebelo
    Negrao, Magda
    Fernandes, Afonso
    Borralho, Paula
    Sobral, Daniel
    Gallego-Paez, Lina M.
    Machado, Daniel
    Gramaca, Joao
    Vilchez, Jose
    Xavier, Ana T.
    Ferreira, Miguel Godinho
    Miranda, Ana R.
    Mansinho, Helder
    Brito, Maria J.
    Pacheco, Teresa R.
    Abreu, Catarina
    Lucia-Costa, Ana
    Mansinho, Andre
    Fior, Rita
    Costa, Luis
    Martins, Marta
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1203 - 1216
  • [50] Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility
    Larsen, Alice Bjerregaard
    Pedersen, Mikkel Wandahl
    Stockhausen, Marie-Therese
    Grandal, Michael Vibo
    van Deurs, Bo
    Poulsen, Hans Skovgaard
    MOLECULAR CANCER RESEARCH, 2007, 5 (03) : 283 - 293
12345